266
Participants
Start Date
December 4, 2017
Primary Completion Date
June 24, 2020
Study Completion Date
June 24, 2021
SGX942
1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
Placebo
Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
University of Rochester, Rochester
University of Virginia, Charlottesville
Spartanburg Regional-Gibbs Cancer Center, Spartanburg
Charleston Cancer Center, Charleston
University Cancer & Blood, Athens
Augusta University, Augusta
Memorial Health, Savannah
Cancer Specialists of North Florida, Jacksonville
Lakes Research, Miami Lakes
Ashland Bellefonte Cancer Center, Ashland
Summa Health Cancer Research, Akron
The Christ Hospital, Cincinnati
Karmanos Cancer Institute, Detroit
Des Moines Oncology Research Association, Des Moines
University of Iowa Hospitals and Clinics, Iowa City
Medical College of Wisconsin, Milwaukee
Minnesota Oncology, Saint Louis Park
Great Falls Clinic, Great Falls
University of Illinois Cancer Center, Chicago
Carle Cancer Center, Urbana
University of Missouri-Ellis Fischel Cancer Center, Columbia
CHI Health St. Francis, Grand Island
Willis Knighton Cancer Center, Shreveport
Mercy Clinic Oncology and Hematology, Oklahoma City
Oklahoma Cancer Specialists, Tulsa
Arizona Clinical Research Center, Tucson
Comprehensive Cancer Centers of Nevada, Henderson
Nevada Cancer Research Foundation, Las Vegas
Pomona Valley Hospital Medical Center, Pomona
Loma Linda University Health, Loma Linda
Providence Regional Cancer Partnership, Everett
Hackensack Meridian Health, Neptune City
Universitair Ziekenhuis Antwerpen, Antwerp
Centre Hospitalier Jolimont, La Louvière
Centre Hospitalier Universitaire de Mons, Mons
CFRO Clinique Pasteur, Brest
Institut Andrée Dutreix, Dunkirk
Clinique Victor Hugo, Le Mans
Hôpital de la Croix Rousse, Lyon
CROM-Osny, Osny
Centre Hospitalier Privé St Grégoire, Saint-Grégoire
Institut Català d'Oncologia Badalona, Badalona
Hospital Universitari Vall d'Hebron, Barcelona
Institut Català d'Oncologia Girona, Girona
Hospital Universitario Severo Ochoa, Leganés
Hospital Regional Universitario de Málaga, Málaga
Hospital Son Llàtzer, Palma de Mallorca
Hospital Universitari Son Espases, Palma de Mallorca
Hospital Clínico Universitario Lozano Blesa, Zaragoza
Aberdeen Royal Infirmary, Aberdeen
Edinburgh Cancer Centre, Edinburgh
Guy's Hospital, London
Weston Park Hospital, Sheffield
Lead Sponsor
Soligenix
INDUSTRY